Less is more after PCI, the TARGET-FIRST trial, a negative blood pressure trial that is actually positive, aspirin vs OAC for bleeding, AEDs, and Factor XI is not dead yet are the topics discussed by John Mandrola, MD, on this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Less is More: TARGET-FIRST
- TARGET-FIRST Trial https://www.nejm.org/doi/10.1056/NEJMoa2508808
- STOPDAPT-2 ACS Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2789701
II A Negative Trial That Is Actually Positive
- The RETREAT-FRAIL Study https://www.nejm.org/doi/full/10.1056/NEJMoa2508157
III Major Bleeding With Aspirin vs Apixaban
- Subanalysis of ARTESiA https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075
- ARTESiA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- AVERROES Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1007432
IV High Value Interventions – The AED
- Experts Call for AED Placement on All Commercial Aircraft https://www.medscape.com/viewarticle/experts-call-aed-placement-all-commercial-aircraft-2025a1000xzf
- In-Flight Sudden Cardiac Arrest and AED Use 10.1016/j.cjca.2025.10.010 External Link
V Factor XI Inhibitors – OCEANIC STROKE trial
- Bayer Press Release on Asundexian https://www.bayer.com/en/us/news-stories/oceanic-stroke
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
